Bond.az - Genentech, a Roche Group member, will present Phase II obesity treatment data at the American Diabetes Association Scientific Sessions.
The company will reveal weight loss outcomes from a 48-week study of enicepatide, a dual GLP-1/GIP agonist.
Data from the ZUPREME-1 trial of petrelintide, a human amylin analog, will also be shared.
Genentech plans to initiate Phase II combination trials by mid-2026.
